Home>>Signaling Pathways>> Endocrinology and Hormones>> Opioid Receptor>>ADL5859 HCl
ADL5859 HCl Catalog No.GC11829

δ-opioid receptor agonist,selective

Size Price Stock Qty
10mM (in 1mL DMSO)
In stock
In stock
In stock
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Chemical Properties

Cas No. 850173-95-4 SDF
Chemical Name N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide;hydrochloride
Canonical SMILES CCN(CC)C(=O)C1=CC=C(C=C1)C2=CC3(CCNCC3)OC4=C2C(=CC=C4)O.Cl
Formula C24H28N2O3.HCl M.Wt 428.95
Solubility ≥ 21.45mg/mL in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).



Selective δ opioid receptor agonists are promising potential therapeutic agents for the treatment of various types of pain conditions. A spirocyclic derivative was identified as a promising hit through screening. ADL5859 is a potent, selective, and orally bioavailable δ opioid receptor agonist.
In vitro: ADL5859 displayed subnanomolar binding affinity at the δ opioid receptor, potent δ agonist activity, and excellent opioid receptor selectivity. Moreover, ADL5859 showed weak inhibitory activity at the hERG channel (78 μM) [1].
In vivo: On the basis of its favorable profile in vitro, ADL5859 was tested in the rat Freund's complete adjuvant (FCA) mechanical hyperalgesia assay. At the screening dose of 3 mg/kg po, ADL5859 produced 100% reversal of hyperalgesia in the inflamed paw. The oral ED50 of ADL5859 in the FCA mechanical hyperalgesia assay was 1.4 mg/kg. The antihyperalgesia produced by ADL5859 (3 mg/kg, po) was reversed by pretreatment with the δ opioid antagonist naltrindole (0.3 mg/kg sc), thus demonstrating a δ receptor mediated effect. Therefore, ADL5859 was selected as a clinical candidate for the treatment of pain [1].
Clinical trial: A clinical study has been conducted to investigate the efficacy and safety of ADL5859 and ADL5747 in participants with pain due to osteoarthritis of the knee, which was supposed to be finished in the middle of 2015.
[1] Le Bourdonnec B, Windh RT, Ajello CW, Leister LK, Gu M, Chu GH, Tuthill PA, Barker WM, Koblish M, Wiant DD, Graczyk TM, Belanger S, Cassel JA, Feschenko MS, Brogdon BL, Smith SA, Christ DD, Derelanko MJ, Kutz S, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE. Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859). J Med Chem. 2008;51(19):5893-6.